{"organizations": [], "uuid": "a8eef94b2fa123def8dd45ad5a44e8d9701c45ba", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180205.html", "section_title": "Archive News &amp; Video for Monday, 05 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-argos-obtains-option-to-license-pd/brief-argos-obtains-option-to-license-pd1-checkpoint-inhibitors-idUSFWN1PV1BQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Argos Obtains Option To License PD1 Checkpoint Inhibitors", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-02-06T05:48:00.000+02:00", "replies_count": 0, "uuid": "a8eef94b2fa123def8dd45ad5a44e8d9701c45ba"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-argos-obtains-option-to-license-pd/brief-argos-obtains-option-to-license-pd1-checkpoint-inhibitors-idUSFWN1PV1BQ", "ord_in_thread": 0, "title": "BRIEF-Argos Obtains Option To License PD1 Checkpoint Inhibitors", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "argos therapeutics inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 5 (Reuters) - Argos Therapeutics Inc:\n* ARGOS OBTAINS OPTION TO LICENSE PD1 CHECKPOINT INHIBITORS\n* ARGOS THERAPEUTICS INC - ENTERED INTO AN OPTION AGREEMENT WITH PHARMSTANDARD INTERNATIONAL, S.A. AND ACTIGEN LIMITED\n* ARGOS THERAPEUTICS INC - UNDER DEAL, CO HAS OPTION TO LICENSE GROUP OF FULLY HUMAN ANTI-PD1 MONOCLONAL ANTIBODIES AND RELATED TECHNOLOGY Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-06T05:48:00.000+02:00", "crawled": "2018-02-07T00:02:35.001+02:00", "highlightTitle": ""}